
Oncoshot
The federated AI data system that increases cancer clinical trial success and patient access to innovative therapies globally.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor | €0.0 | round |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
* | N/A | Seed | |
Total Funding | 000k |
USD | 2021 | 2022 | 2023 |
---|---|---|---|
Revenues | 0000 | 0000 | 0000 |
% growth | - | 144 % | 36 % |
EBITDA | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Oncoshot is a healthcare technology company specializing in connecting cancer patients, caregivers, and oncologists with relevant clinical trials globally. Operating in the oncology sector, Oncoshot leverages advanced data analytics to match patients with suitable clinical trials based on their unique medical profiles. The platform serves a diverse clientele, including cancer patients seeking new treatment options, caregivers looking for the best care solutions, and oncologists aiming to provide cutting-edge treatments to their patients. Oncoshot's business model revolves around offering a free trial matching service, which is monetized through partnerships with trial sponsors and medical institutions. These partners benefit from streamlined patient recruitment processes, enhancing the efficiency and success rates of their clinical trials. By facilitating direct connections between patients and trial sponsors, Oncoshot ensures timely and personalized trial information, thereby accelerating the path to potential treatments. The company operates in the rapidly evolving landscape of cancer care, addressing the critical issue of trial accessibility and patient engagement.
Keywords: cancer, clinical trials, oncology, patient matching, data analytics, healthcare technology, trial sponsors, patient recruitment, personalized medicine, global reach.